Asset Details
Do you wish to reserve the book?
Reduced Ocular Surface Inflammation in SMILE Patients: The Beneficial Outcome of 0.1% Ciclosporin Cationic Emulsion Treatment
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Reduced Ocular Surface Inflammation in SMILE Patients: The Beneficial Outcome of 0.1% Ciclosporin Cationic Emulsion Treatment
Do you wish to request the book?
Reduced Ocular Surface Inflammation in SMILE Patients: The Beneficial Outcome of 0.1% Ciclosporin Cationic Emulsion Treatment
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Reduced Ocular Surface Inflammation in SMILE Patients: The Beneficial Outcome of 0.1% Ciclosporin Cationic Emulsion Treatment
2025
Overview
After laser refractive surgery, dry eye disease is a common issue, primarily caused by inflammation. In a cohort of patients undergoing small incision lenticule extraction (SMILE), we examined the impact of anti-inflammatory drug ciclosporin (0.1% in cationic emulsion; CsA-CE) on the corneal fluorescein staining (CFS) score and other indicators of dry eye disease.
This non-randomized, interventional, comparative study enrolled 30 patients undergoing SMILE, who received a once-daily, preservative-free, single-dose formulation of CsA-CE for one month following surgery. Tear osmolarity, ocular surface disease index (OSDI) scores, and CFS scores were measured after one- and three-months following surgery and compared to a control group (n=30). In the CsA-CE group, 26 patients completed the follow-up at Month 1, compared to 28 patients in the control group. At three-months follow-up, 22 patients in the CsA-CE group and 23 in the control group remained.
At Month 1 and Month 3 postoperative follow-up, the CsA CE group's CFS scores were significantly lower compared to controls: 0.31 ± 0.74 vs 0.75 ± 0.89 (P = 0.02) and 0.05 ± 0.21 vs 0.43 ± 0.84 (P = 0.04), respectively. Mean CFS scores of CsA-CE group were 0.44 (Month 1) and 0.38 (Month 3) lower postoperatively, compared to the control group. Tear osmolarity and OSDI scores, however, did not significantly differ between the two groups and stayed within normal bounds. With 57.7% of patients reporting no instillation site pain and no other side effects, the treatment was well-tolerated.
The anti-inflammatory effect of CsA-CE application in the early postoperative period after SMILE resulted in significantly lower CFS scores at Months 1 and 3 in comparison to the control group. These results suggest that 0.1% CsA-CE treatment lowers ocular surface damage and might thus benefit the recovery process of patients treated with this form of laser refractive surgery.
We currently cannot retrieve any items related to this title. Kindly check back at a later time.